EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection of cardiac amyloidosis on routine bone scintigraphy: an important gatekeeper role for the nuclear medicine physician

Mohit Nebhwani, Karina Chaibekava, Anouk Achten, Marish I F J Oerlemans, Michelle Michels, Peter van der Meer, Hans L A Nienhuis, Jerremy Weerts, Vanessa van Empel, Hans-Peter Brunner-La Rocca, Sandra Sanders-van Wijk, Jochem van der Pol und 1 weitere

The International Journal of Cardiovascular Imaging · 2024

DOI: 10.1007/s10554-024-03085-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Cardiovascular Imaging, 2024. Verfasst von Mohit Nebhwani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center+, PO Box 5800, 6202 AZ, Maast…. Hauptthemen laut MEDLINE: Predictive Value of Tests, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac amyloidosis (CA)—mostly transthyretin-related (ATTR-CA)—has recently gained interest in cardiology. Bone scintigraphy (BS) is one of the main screening tools for ATTR-CA but also used for various other reasons. The objective was to evaluate whether all CA cases are detected and what happens during follow-up. All routine BS performed at the Maastricht University Medical Center (May 2012–August 2020) were screened for the presence of CA. Scans performed for suspected CA were excluded. A Perugini stage ≥1 was classified as positive necessitating further examination. The electronic medical record system was evaluated for any contact with cardiology or other specialists until 2021. Of the 2738 BS evaluated, 40 scans (1.46%; median age 73.5 [IQR: 65.8–79.5], 82.5% male) were positive (Perugini grade 1: 31/77.5%, grade 2: 6/15%, grade 3: 3/7.5%); the potential diagnosis ATTR-CA was not seen in 38 patients (95%) by the nuclear medicine specialist. During follow-up, 19 out of those 40 patients (47.5%) underwent cardiac evaluation without diagnosing CA. Available echocardiograms of patients with a positive BS showed left ventricular hypertrophy, a preserved ejection fraction, and diastolic dysfunction ≥2 in 9/47%, 10/53%, and 4/21% of patients, respectively. Additionally, 20 (50%) patients presented to at least one specialty with symptoms indicative of cardiac amyloidosis. The prevalence of a positive BS indicating potential CA in an unselected population is low but substantial. The majority was not detected which asks for better awareness for CA of all involved specialists to ensure appropriate treatment and follow-up. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Predictive Value of TestsAmyloid Neuropathies, FamilialCardiomyopathiesHumansMaleAgedFemaleRadionuclide ImagingRadiopharmaceuticalsNetherlandsRetrospective StudiesBone and BonesAged, 80 and overTime Factors

Stichwörter der Autor:innen

99mTc-HDPAmyloidosisBonescintigraphyEchocardiographyFollow-upPrevalence

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Cardiology and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center+, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Department of Cardiology, Universitair Medisch Centrum, Utrecht, The Netherlands.
  • Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thoraxcenter, Rotterdam, The Netherlands.
  • Department of Cardiology, University Medical Center, Groningen, The Netherlands.
  • Department of Rheumatology & Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands.

Zitieren

APA

Nebhwani, M., Chaibekava, K., Achten, A., Oerlemans, M. I. F. J., Michels, M., van der Meer, P., Nienhuis, H. L. A., Weerts, J., van Empel, V., Rocca, H. B., Wijk, S. S., van der Pol, J., & Knackstedt, C. (2024). Detection of cardiac amyloidosis on routine bone scintigraphy: an important gatekeeper role for the nuclear medicine physician. The International Journal of Cardiovascular Imaging. https://doi.org/10.1007/s10554-024-03085-z

Vancouver

Nebhwani M, Chaibekava K, Achten A, Oerlemans MIFJ, Michels M, van der Meer P, et al. Detection of cardiac amyloidosis on routine bone scintigraphy: an important gatekeeper role for the nuclear medicine physician. The International Journal of Cardiovascular Imaging. 2024. doi:10.1007/s10554-024-03085-z

BibTeX
@article{Nebhwani2024,
  author = {Nebhwani, Mohit and Chaibekava, Karina and Achten, Anouk and Oerlemans, Marish I F J and Michels, Michelle and van der Meer, Peter and Nienhuis, Hans L A and Weerts, Jerremy and van Empel, Vanessa and Rocca, Hans-Peter Brunner-La and Wijk, Sandra Sanders-van and van der Pol, Jochem and Knackstedt, Christian},
  title = {Detection of cardiac amyloidosis on routine bone scintigraphy: an important gatekeeper role for the nuclear medicine physician},
  journal = {The International Journal of Cardiovascular Imaging},
  year = {2024},
  doi = {10.1007/s10554-024-03085-z}
}
Kostenlos starten →